Abbott's Kaletra Promotions Overstate Length Of Efficacy, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A poster and print ad for the protease inhibitor combo make the unsubstantiated claim that patients taking Kaletra "can expect to survive and be healthy" for five years, FDA says. Abbott releases six-year Kaletra data at ICAAC conference.